Genelux (NASDAQ:GNLX) Receives Buy Rating from HC Wainwright

Genelux (NASDAQ:GNLX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $30.00 price objective on the stock. HC Wainwright also issued estimates for Genelux’s Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Trading Down 5.9 %

GNLX stock opened at $3.20 on Tuesday. The firm’s 50-day moving average is $4.03 and its two-hundred day moving average is $3.09. The company has a market capitalization of $110.52 million, a price-to-earnings ratio of -3.37 and a beta of -1.41. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50.

Hedge Funds Weigh In On Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GNLX. Geode Capital Management LLC lifted its holdings in shares of Genelux by 39.7% in the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after buying an additional 89,854 shares during the period. Marshall Wace LLP lifted its holdings in Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after acquiring an additional 52,958 shares during the last quarter. LPL Financial LLC lifted its holdings in Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after acquiring an additional 39,516 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Genelux during the 3rd quarter valued at about $59,000. Finally, D.A. Davidson & CO. acquired a new position in shares of Genelux in the 4th quarter worth approximately $51,000. 37.33% of the stock is owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.